Abstract
A DBU-catalyzed one-pot multicomponent reaction involving indane-1,3-dione, aldehydes, and 1,4-dithiane-2,5-diol for the synthesis of spirocyclic tetrahydrothiophene derivatives has been developed. A series of spirocyclic tetrahydrothiophene derivatives were obtained in generally good to excellent yields with high diastereoselectivity via this synthetic strategy. Importantly, this methodology has several advantages, such as mild reaction conditions, broad scope of substrates, easy operations and so on.
Keywords: Aldehydes, DBU, 1, 4-dithiane-2, 5-diol, indane-1, 3-dione, multi-component reaction, one-pot, organocatalysis, tetrahydrothiophene.
Current Organocatalysis
Title:DBU-Catalyzed One-Pot Multicomponent Reaction for the Synthesis of Spirocyclic Tetrahydrothiophene Derivatives
Volume: 3 Issue: 2
Author(s): Jindian Duan, Jing Cheng and Pengfei Li
Affiliation:
Keywords: Aldehydes, DBU, 1, 4-dithiane-2, 5-diol, indane-1, 3-dione, multi-component reaction, one-pot, organocatalysis, tetrahydrothiophene.
Abstract: A DBU-catalyzed one-pot multicomponent reaction involving indane-1,3-dione, aldehydes, and 1,4-dithiane-2,5-diol for the synthesis of spirocyclic tetrahydrothiophene derivatives has been developed. A series of spirocyclic tetrahydrothiophene derivatives were obtained in generally good to excellent yields with high diastereoselectivity via this synthetic strategy. Importantly, this methodology has several advantages, such as mild reaction conditions, broad scope of substrates, easy operations and so on.
Export Options
About this article
Cite this article as:
Duan Jindian, Cheng Jing and Li Pengfei, DBU-Catalyzed One-Pot Multicomponent Reaction for the Synthesis of Spirocyclic Tetrahydrothiophene Derivatives, Current Organocatalysis 2016; 3 (2) . https://dx.doi.org/10.2174/2213337202666150414201456
DOI https://dx.doi.org/10.2174/2213337202666150414201456 |
Print ISSN 2213-3372 |
Publisher Name Bentham Science Publisher |
Online ISSN 2213-3380 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fermented Grape Marc (FGM): Immunomodulating Properties and its Potential Exploitation in the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Effects of Lipid-Lowering Drugs on Adiponectin
Current Vascular Pharmacology Nitric Oxide, Epileptic Seizures, and Action of Antiepileptic Drugs
CNS & Neurological Disorders - Drug Targets Delivering the "Blueprints" or "DNA Repairing Kits" Instead of Drugs in the Treatment of Congenital Hemoglobinopathies
Current Organic Chemistry Current and Future Applications of Probiotics
Current Nutrition & Food Science Complement: An Inflammatory Pathway Fulfilling Multiple Roles at the Interface of Innate Immunity and Development
Current Drug Targets - Inflammation & Allergy Lysophospholipid Receptors as Potential Drug Targets in Tissue Transplantation and Autoimmune Diseases
Current Pharmaceutical Design Neuroprotection by Natural Polyphenols: Molecular Mechanisms
Central Nervous System Agents in Medicinal Chemistry Role of Poly(ADP-ribose) Polymerase (PARP1) in Viral Infection and its Implication in SARS-CoV-2 Pathogenesis
Current Drug Targets Morphological and Functional Characteristic of Senescent Cancer Cells
Current Drug Targets Synthesis and Anti-Inflammatory Activity of Fused 1,2,4-triazolo-[3,4-b] [1,3,4]thiadiazole Derivatives of Phenothiazine
Letters in Drug Design & Discovery Pharmacogenetics Strategies: From Candidate Genes to Whole-Genome Association Analysis. Exploratory or Confirmatory Studies?
Current Pharmacogenomics and Personalized Medicine Novel Approaches for Inhibition of Mucus Hypersecretion in Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Melanoma Adjuvant Treatment: Current Insight and Clinical Features
Current Cancer Drug Targets Exosomal miR-214-5p Released from Glioblastoma Cells Modulates Inflammatory Response of Microglia after Lipopolysaccharide Stimulation through Targeting CXCR5
CNS & Neurological Disorders - Drug Targets HDAC Inhibitors-New Generation of Target Specific Treatment
Mini-Reviews in Medicinal Chemistry Cytotoxicity and Toxicity to Animals and Humans of Ribosome-Inactivating Proteins
Mini-Reviews in Medicinal Chemistry Chondromodulin-I and Tenomodulin: The Negative Control of Angiogenesis in Connective Tissue
Current Pharmaceutical Design Drug Tissue Distribution: Study Methods and Therapeutic Implications
Current Pharmaceutical Design EGFR Intron Recombination in Human Gliomas: Inappropriate Diversion of V(D)J Recombination?
Current Genomics